RTP Mobile Logo
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Gastroesophageal Cancers (Webinar Video Proceedings)
Released February 2022

Featuring perspectives from Dr Yelena Janjigian, Prof Eric Van Cutsem and Dr Harry Yoon, moderated by Dr Samuel Klempner. Published February 25, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastroesophageal cancers.

    LEARNING OBJECTIVES

    • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
    • Describe the published research data with approved and investigational anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancers, and consider the current and future placement of these strategies in treatment algorithms.
    • Optimally incorporate available therapeutic agents and regimens into the care of patients with HER2-negative metastatic gastric, GEJ or esophageal cancer who have experienced disease progression on front-line chemotherapy or chemoimmunotherapy.
    • Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease, and discern the clinical applicability of this treatment strategy.
    • Recall available data with novel HER2-targeted agents and strategies for patients with newly diagnosed or previously treated HER2-overexpressing gastric or GEJ cancer, and identify candidates who may be appropriate for these approaches.
    • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
    • Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOGI22/Gastric/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:

    FACULTY

    Yelena Y Janjigian, MD
    Associate Professor
    Chief of Gastrointestinal Oncology Service
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Imugene, Lilly, Merck, Merck Serono, MJH Life Sciences, Pfizer Inc, Rgenix, Seagen Inc, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cycle for Survival, Fred's Team, Genentech, a member of the Roche Group, Lilly, Merck, National Cancer Institute, Rgenix, US Department of Defense; Stock Options: Rgenix.

    Eric Van Cutsem, MD, PhD
    Professor of Medicine
    Digestive Oncology
    University Hospitals Leuven
    Leuven, Belgium

    Advisory Committee: AbbVie Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation, TRIGR (trial), Zymeworks Inc; Research Grants to Institution: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC.

    Harry H Yoon, MD
    Associate Professor of Oncology
    Co-Chair, Gastroesophageal Cancer Disease Group
    Mayo Clinic Comprehensive Cancer Center
    Rochester, Minnesota

    Advisory Committee: ALX Oncology, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, MacroGenics Inc, Merck, Novartis, OncXerna Therapeutics Inc, Zymeworks Inc; Contracted Research: BeiGene Ltd, Bristol-Myers Squibb Company, CARsgen Therapeutics, Merck, Sumitomo Dainippon Pharma Oncology Inc.

    Moderator

    Samuel J Klempner, MD
    Associate Professor
    Massachusetts General Hospital
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Merck, Natera Inc, Pieris Pharmaceuticals Inc; Consulting Agreement: Lilly; Contracted Research (to Institution): BeiGene Ltd (clinical trial); Ownership Interest: Turning Point Therapeutics Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Coherus BioSciences, Daiichi Sankyo Inc and Lilly.

    Release date: February 2022
    Expiration date: February 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):